Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.
AUTOR(ES)
Lumbreras, C
RESUMO
The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=192416Documentos Relacionados
- Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.
- The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir
- Risk of liver disease in HCV-seropositive kidney transplant recipients.
- Active Lymphocytic Myocarditis Treated with Murine OKT3 Monoclonal Antibody: in a Patient Presenting with Intractable Ventricular Tachycardia
- OKT3 and cerebral oedema.